Clinical Trial Update: TGD001 Treatment in Thrombotic Microangiopathies [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for TGD001 in thrombotic microangiopathy and immune thrombocytopenia, currently not recruiting for Phase 1/Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia
• Thrombotic Microangiopathy

Drugs mentioned

• TGD001 (TGD001)

Snippet

Sponsor: TargED Biopharmaceuticals B.V. | Conditions: Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING